作　　者： (李泽桦）; (陈敏生）;

机构地区： 南方医科大学,广东广州510515

出　　处： 《中国微生态学杂志》 2017年第8期975-979,共5页

摘　　要： 动脉粥样硬化(atherosclerosis,AS)是冠心病(coronary atherosclerotic heart disease,CAD)的发病基础。参与AS形成的原因有很多,近年来的研究表明依赖肠道菌群的胆碱代谢物氧化三甲胺(trimethylamine oxide,TMAO)也与AS的发生、发展有关。天然药物具有生物多效性,有研究表明其中的多酚类成分可通过影响肠道菌群的多样性减少AS的风险。本文就天然药物与肠道菌群和AS关系的研究进展进行综述。 Coronary atherosclerotic heart disease（CAD）is found to be strongly associated with atherosclerosis（AS）.There are many factors involved in the formation of AS.Recently,researchers have found that trimethylamine-N-oxide（TMAO）,agut microbiota-dependent choline metabolites,is also an independent risk factor for the development of AS.Natural medicines have biological pleiotropy.Studies have shown that the polyphenols in natural medicines can reduce the risk of AS development via remodeling of gut microbiota.In this review,the relationship of natural medicines with gut microbiota and AS were discussed,which might provide a new potential therapeutic target for the prevention and treatment of CAD.

关 键 词： 天然药物 动脉粥样硬化 冠心病 肠道菌群 氧化三甲胺